DURECT (NASDAQ:DRRX) Coverage Initiated by Analysts at StockNews.com
Investment analysts at StockNews.com began coverage on shares of DURECT (NASDAQ:DRRX – Get Free Report) in a research note issued on Sunday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock. Separately, HC Wainwright reaffirmed a “neutral” rating on shares of DURECT in a report on Thursday, November 14th. Check Out Our […]
Investment analysts at StockNews.com began coverage on shares of DURECT (NASDAQ:DRRX – Get Free Report) in a research note issued on Sunday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock. Separately, HC Wainwright reaffirmed a “neutral” rating on shares of DURECT in a report on Thursday, November 14th. Check Out Our […]
